ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Comprehensive Analysis of RAPGEF2 for Predicting Prognosis and Immunotherapy Response in Patients with Hepatocellular Carcinoma

Wu, Qing; Hu, Yangzhi; Ma, Qinghui; Yang, Shanglin; Chen, Junpeng; Wen, Shunqian*; Liao, Guanqun*南方医科大学
Journal of Oncology2022-4-26DOI: 10.1155/2022/6560154
1被引7阅读
引用收藏
分享

摘要

Background. Hepatocellular carcinoma (HCC) is the sixth most common tumor worldwide. Additionally, deletion of RAPGEF2 plays a critical role in CNV and related to tumor immune microenvironment, whereas the prognostic potential of RAPGEF2 in HCC patient needs to be explored. Methods. We looked for prognostic potential genes in HCC using a variety of R programs. Then, using the LASSO Cox regression, we thoroughly evaluated and integrated the RAPGEF2-related genes from TCGA database. Meanwhile, utilizing TCGA and ICGA databases, the link between RAPGEF2 and immunotherapy response in HCC was studied. In vivo, the effect of RAPGEF2 on tumor development and the capacity of natural killer (NK) cells to recruit were confirmed. To ascertain the connection between RAPGEF2-related genes and the prognosis of HCC, a prognostic model was created and validated. Result. We demonstrated RAPGEF2 has a differential expression, and patients with deletion of RAPGEF2 gene get shorter survival in HCC. Additionally, the tissues without RAPGEF2 have a weaker ability to recruit the NK cells and response to immunotherapy. After that, we scoured the database for eight RAPGEF2-related genes linked with a better prognosis in HCC patients. Additionally, silencing RAPGEF2 accelerated tumor development in the HCC mouse model and decreased CD56+ NK cell recruitment in HCC tissues. TCGA database was used to classify patients into low- and high-risk categories based on the expression of related genes. Patients in the low-risk group had a significantly greater overall survival than those in the high-risk group (P < 0.001). Meanwhile, the low-risk group demonstrated connections with the NK cell and immunotherapy response. Finally, the prognostic nomogram showed a high sensitivity and specificity for predicting the survival of HCC patients at 1, 2, and 3 years. Conclusion. The prognostic model based on RAPGEF2 and RAPGEF2-related genes showed an excellent predictive performance in terms of prognosis and immunotherapy response in HCC, therefore establishing a unique prognostic model for clinical assessment of HCC patients.

学科与关键词

关键词
METASTASISMUTATIONSHETEROGENEITYNUCLEOTIDEEXPRESSION
相关
加载中…
  • Characterization of prognostic value and immunological roles of RAB22A in hepatocellular carcinoma
    Wen, Fukai; Meng, Fanshuai; Li, Xuewen; Li, Qingyu; Liu, Jiaming; Zhang, Rui; Zhao, Yunzheng; Zhang, Yu; Wang, Xin; Ju, Shuai; Cui, Yifeng*; Lu, Zhaoyang*Frontiers in Immunology, 2023, 14: 1086342.被引 3
  • Identification of Prognosis-Related Oxidative Stress Model with Immunosuppression in HCC
    Ren, Zhixuan; Zhang, Jiakang; Zheng, Dayong; Luo, Yue; Song, Zhenghui; Chen, Fengsheng; Li, Aimin*; Liu, Xinhui*Biomedicines, 2023, 11(3): 695.被引 1
  • Construction of HBV gene-related prognostic and diagnostic models for hepatocellular carcinoma
    Ma, Keqiang; Wu, Hongsheng*; Ji, Lei*Frontiers in Genetics, 2023, 13: 1065644.
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Oncology
发表日期
2022-04-26
卷期
第 2022 卷
页码
6560154
DOI
10.1155/2022/6560154
期刊等级
4区
成果收录
SCIE
资助标注
Medical Scientific Research Foundation of Guangdong Province of China [B2021319]; Project of Administration of Traditional Chinese Medicine of Guangdong Province of China [20202183]; GuangDong Basic and Applied Basic Research Foundation [2020A1515110097]

作者

  • W

    Wu, Qing (第一作者)

    2 · southern med univ

  • H

    Hu, Yangzhi

    xiangnan univ

查看全部 7 位作者收起作者
  • M

    Ma, Qinghui

    2 · southern med univ

  • Y

    Yang, Shanglin

    2 · southern med univ

  • C

    Chen, Junpeng

    2 · southern med univ

  • W

    Wen, Shunqian (通讯)

    2 · southern med univ

  • L

    Liao, Guanqun (通讯)

    2 · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417